Quipt Home Medical Corp T.QIPT

Alternate Symbol(s): QIPT

Healthcare Medical Care

Quipt Home Medical Corp. is a home medical equipment provider. The Company specializes in improving the home management of chronic illness through the application of telehealth systems and automated distribution. It provides in-home monitoring and disease management services, including end-to-end respiratory solutions for patients in the United States. It offers nebulizers, oxygen concentrators, continuous positive airway pressure (CPAP) and Bilevel Positive Airway Pressure (BiPAP) units; traditional and non-traditional medical respiratory equipment and services, and non-invasive ventilation equipment, supplies, and services. The Company's product offerings include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. Its products and services consist of sleep apnea and pap treatment, home ventilation, daily and ambulatory aides, and respiratory equipment rental.

TSX:QIPT - Post by User

Quipt Home Medical Corp > M PARTNERS, $3.50PT

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Feb 01, 2021 8:22pm

341 Views

Post# 32442876

RE:RE:M PARTNERS, $3.50PT

I guessed too low. M Partners estimates 2022 ebitda of $38 mil, 83% growth over 2 years.

https://www.protechhomemedical.com/pdf/20210201%20-%20M%20Partners%20-%20PTQ%20-%20Q4%20Results.pdf

lscfa wrote:

2022 ebitda forecast = $3.50 x 112.5 mil shs / 11 multiple = $35.8 mil vs. $20.8 mil for 2020, 72% growth over 2 years.

Additionally, Protech is currently pursuing an uplisting to the NASDAQ which will increase PTQ’s exposure and accessibility to U.S. capital markets. As a result, we believe Protech presents a unique buying opportunity ahead of U.S. institutional fund flows. We are maintaining our BUY recommendation and increasing our target price to $3.50/share (from $2.50/share) based on 11x 2022 EBITDA (from 9x 2021 EBITDA).